Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | CBFB | Q13951 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211832 | 0.83 | KMT2A (0.38) | KMT2APOLBALDH1A1USP2HPGD | |
| SCHEMBL207131 | 0.75 | ALPL (0.41) | KMT2AKDM4EMETAP2METAP1CBFB | |
| SCHEMBL10973210 | 0.75 | PRKCI (0.47) | KMT2APOLBALDH1A1USP2HPGD | |
| SCHEMBL416318 | 0.74 | FABP6 (0.41) | KMT2APOLBALDH1A1HPGDCYP1A2 | |
| SCHEMBL11227448 | 0.72 | NPBWR1 (0.47) | CBFB | |
| SCHEMBL9162899 | 0.71 | NPC1 (0.48) | KMT2APOLBALDH1A1USP2HPGD | |
| SCHEMBL15540652 | 0.70 | QPCT (0.31) | — | |
| SCHEMBL2862 | 0.69 | — | — | |
| SCHEMBL7266407 | 0.68 | XDH (0.42) | KMT2APOLBALDH1A1HPGDHTT | |
| SCHEMBL16293605 | 0.68 | GRIN2D (0.41) | KMT2AHTTGAAPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536646-A | Nematicidal active compound and preparation method and application thereof | 华东理工大学 | 2022-12-30 | — | — | CN | disclosed |
| CN-103342705-A | Method for synthesizing pyrrole [1,2-a ] quinoxaline derivative | NANJING UNIVERSITY OF TECHNOLOGY | 2013-10-09 | — | — | CN | disclosed |
| CN-103333171-A | Synthetic method of pyrrole [1,2-a ] quinoxaline derivative | NANJING UNIVERSITY OF TECHNOLOGY | 2013-10-02 | — | — | CN | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
| EP-1660080-A1 | FURANONE DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016340-A1 | FURANONE DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-0744948-A4 | PROTEASE INHIBITORS | LILLY CO ELI (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5624934-A | PREVENTING HIV INFECTION | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0744948-A1 | PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5480887-A | FOR HIV, THIENO(3,2-C)PYRIDINE-(6S)-CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995020962-A1 | PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| EP-0034116-A2 | N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1981-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | KMT2A 253/4885POLB 4374/4885ALDH1A1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.